Op2Lysis SAS is pleased to announce that the US Food and Drug Administration (FDA) has granted Orphan Drug Designation to OptPA for treatment of intracerebral hemorrhage.
Op2Lysis SAS is pleased to announce that the US Food and Drug Administration (FDA) has granted Orphan Drug Designation to OptPA for treatment of intracerebral hemorrhage.